Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 12Cisplatin 10pembrolizumab 7Fluorouracil 7Leucovorin 6Oxaliplatin 5durvalumab 3Capecitabine 3zanidatamab 2Paclitaxel 2Irinotecan 2Folfox protocol 2Bevacizumab 2vandetanib 1tucatinib 1trastuzumab deruxtecan 1seribantumab 1merestinib 1lenvatinib 1irinotecan sucrosofate 1galactomannan 1fludarabine 1exatecan 1bintrafusp alfa protein, human 1becatecarin 1aldesleukin 1Trastuzumab 1Temozolomide 1Tegafur 1S 1 (combination) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gallbladder Neoplasms × galactomannan × Clear all
NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡